Elevated Plasma Complement Factors in CRB1-associated **Inherited Retinal Dystrophies**

Lude Moekotte,¹ Joke H. de Boer,¹ Sanne Hiddingh,¹ Aafke de Ligt,¹ Xuan-Thanh-An Nguyen,² Carel B. Hoyng,³ Chris F. Inglehearn,⁴ Martin McKibbin,^{4,5} Tina M. Lamey,⁶ Jennifer A. Thompson,⁷ Fred K. Chen,^{6,7} Terri L. McLaren,^{6,7} Alaa AlTalbishi,⁸ Daan M. Panneman,⁹ Erica G.M. Boonen,⁹ Sandro Banfi,^{10,11} Béatrice Bocquet,^{12,13} Isabelle Meunier,^{12,13} Elfride De Baere,^{14,15} Robert Koenekoop,^{16,17} Monika Ołdak,¹⁸ Carlo Rivolta,^{19,20,21} Lisa Roberts,²² Raj Ramesar,²² Rasa Strupaitė-Šileikienė,²³ Susanne Kohl,²⁴ G. Jane Farrar,²⁵ Marion van Vugt,²⁶ Jessica van Setten,²⁶ Susanne Roosing,⁹ L. Ingeborgh van den Born,²⁷ Camiel J.F. Boon,^{2,28} and Maria M. van Genderen,^{1,29}, Jonas J.W. Kuiper¹

Department of Ophthalmology, St. James's University Hospital, Leeds, United Kingdom

St John of Jerusalem Eye Hospital Group, East Jerusalem, Palestine

¹⁰ Telethon Institute of Genetics and Medicine, Pozzuoli, Italy

¹¹ Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy

Word count:

Word count main text (excl. title page, legends, and references):

Funding: Bartimeus Foundation (LM, JHdB, SH, AdL, XN, LlvdB, CB, MMvG, JJWK), VHRN vision health research network and FBC fighting blindness Canada (RK), Swiss National Science Foundation (grant 204285) and European Union (grant EJP-RD19-234, Solve-Ret) (CR)

¹ Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands

² Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands

³ Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands

Division of Molecular Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, United

Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Western Australia, Australia

Australian Inherited Retinal Disease Registry & DNA Bank, Department of Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands

¹² Institute for Neurosciences of Montpellier (INM), University of Montpellier, INSERM, Montpellier, France

¹³ National Reference Center for Inherited Sensory Diseases, University of Montpellier, CHU, Montpellier, France

¹⁴ Department of Biomolecular Medicine, Ghent University, Ghent, Belgium

¹⁵ Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium

¹⁶ McGill University Health Center (MUHC) Research Institute, Montreal, QC, Canada

¹⁷ Departments of Paediatric Surgery, Human Genetics, and Adult Ophthalmology, McGill University Health Center, Montreal, QC, Canada

Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland

¹⁹ Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland

²⁰ Department of Ophthalmology, University of Basel, Basel, Switzerland

²¹ Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom

²² UCT/MRC Precision and Genomic Medicine Research Unit, Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

²³ Center of Eye Diseases, Clinic of Ear, Nose, Throat, and Eye Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany

The School of Genetics & Microbiology, The University of Dublin Trinity College, Dublin, Ireland

²⁶ Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands

²⁷ Department of Ophthalmology, Het Oogziekenhuis Rotterdam, Rotterdam, the Netherlands

Department of Ophthalmology, Amsterdam UMC, Amsterdam, the Netherlands

²⁹ Bartiméus, Diagnostic Centre for complex visual disorders, Zeist, the Netherlands

Abstract

Objective: To determine the profile of inflammation-related proteins and complement

system factors in serum of CRB1-associated inherited retinal dystrophies (CRB1-IRDs).

Design: A case-control study.

Subjects, Participants, and/or Controls: A cohort of 30 Dutch CRB1-IRD patients and 29

Dutch healthy controls (HC) (Cohort I), and a second cohort of 123 CRB1-IRD patients from

14 countries and 1292 controls (Cohort II) were used in this study.

Methods: Quantitative 370-plex targeted proteomics in blood plasma and genotyping of the

single nucleotide variant (SNV) rs7535263 in the CFH gene.

Main Outcome Measures: Plasma concentrations of inflammation-related proteins and the

genotype of the SNV rs7535263.

Results: CRB1-IRD patients showed increased plasma levels of complement system and

coagulation cascade proteins compared to healthy controls. Complement Factor I [CFI],

Serpin Family D1 [SERPIND1], and Complement Factor H [CFH] were significantly elevated

(q<0.05, adjusted for age and sex), which correlated (Pearson's correlation coefficient >0.6)

with higher levels of plasma Complement Component 3 [C3] (q = 0.064). The most enriched

pathway in patients was the "Complement cascade" (R-HSA-166658, $Padj = P = 3.03 \times 10^{-1}$

¹⁵). An analysis of the genotype of *CFH* variant rs7535263, which is in close physical

proximity to the CRB1 gene and is associated with other retinal conditions by influencing

plasma complement levels, revealed significantly skewed allele distribution specifically in

Dutch patients (A allele of rs7535263, odds ratio (OR) [95%CI = 2.85 [1.35-6.02], $P = 6.19 \times 10^{-2}$

 10^{-3}), but not in a global case-control cohort (P = 0.12). However, CRB1 missense variants

that are common in patients display strong linkage disequilibrium (LD) with rs7535263 in

CFH in the UK Biobank (D' = 0.97 for p.(Cys948Tyr); D' = 1.0 for p.(Arg764Cys)), indicating

that genetic linkage may influence plasma complement factor levels in CRB1-IRD patients.

2

After accounting for the CFH genotype in the proteomic analyses, we also detected

significantly elevated plasma levels of Complement Factor H Related 2 [CFHR2] in CRB1-

IRD patients (q = 0.04).

Conclusions: CRB1-IRDs are characterized by changes in plasma levels of complement

factors and proteins of the innate immune system, which is influenced by common functional

variants in the CFH-CFHR locus. This indicates that innate immunity is implicated in CRB1-

IRDs.

Keywords: inherited retinal dystrophy, CRB1, proteomics, complement, CFH, inflammation

Introduction

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

The Crumbs homolog 1 (CRB1) gene (also known as RP12) is a transmembrane protein that functions in the integrity preservation of the photoreceptor layer of the retina. CRB1 pathogenic variants cause a spectrum of rare autosomal recessive inherited retinal dystrophies (CRB1-IRDs) characterized by photoreceptor cell death and early visual impairment.¹⁻³ There are many pathogenic variants associated with *CRB1*-IRDs, and the clinical phenotypes vary considerably in severity of disease.^{1,3} Although some correlation between CRB1 genotype and clinical phenotypes can be found.4 overall there is surprisingly little genotype-phenotype correlation, even among cases with identical pathogenic variants.^{1,3} Therefore, it has been hypothesized that phenotypic variation among patients may be caused by factors other than the underlying CRB1 pathogenic variants.¹ The presence of vitreous inflammation or cystoid macular edema (CME) in some patients with CRB1-IRDs suggests that inflammatory pathways may be involved in the pathophysiology, 5,6 Indeed, inflammatory genes and complement factors are upregulated in the retinas of rd8 mice homozygous for a *Crb1* gene pathogenic variant. 1,5-9 Furthermore, we previously showed that patients with CRB1-IRDs exhibit changes in their peripheral blood T cells and dendritic cells. 6,10 These findings suggest that variability of immune responses between patients may contribute to differential clinical phenotypes, but there have been few studies that examine the immune profiles of CRB1-IRD patients. 6,10 A way to study immune profiles is by examining blood proteins, which contribute to immune responses and function by modifying the signaling of cytokines, triggering acute-phase reactions, and activating complement cascades. Targeted proteomics allows the accurate quantification of hundreds of blood proteins in patient samples to determine, in-depth, the immune profile of disease and identify disease-related mechanisms. 11 This technique has provided insight in the blood proteome of diverse eye conditions such as age-related

- 26 macular degeneration (AMD), retinopathy of prematurity, uveitis, uveal melanoma, and
- 27 diabetic retinopathy. 12–18
- 28 In this study, we conducted targeted 370-plex proteomics of blood plasma proteins in CRB1-
- 29 IRD patients and healthy controls to determine the plasma concentrations of inflammation-
- related proteins. In the same cohort, and in a validation cohort, we determined the CFH gene
- 31 variant rs7535263 to test for associations between protein expression and genotype.

Methods

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Patients

This study was performed in compliance with the guidelines of the Declaration of Helsinki and has the approval of the local Institutional Review Board (University Medical Center Utrecht (UMCU)). In total, 30 patients were referred to the UMCU from the Amsterdam University Medical Centers, Leiden University Medical Center, Bartiméus Diagnostic Center for complex visual disorders, The Rotterdam Eye Hospital and Rotterdam Ophthalmic Institute, and Groningen University Medical Center for recruitment at the outpatient clinic of the department of Ophthalmology of the UMCU (MEC-14-065). Each patient provided written informed consent before participation and blood collection. The *CRB1*-IRD diagnosis was established by ophthalmic examination, imaging, full field electroretinography, and next-generation sequencing or whole-exome sequencing. Patients were considered to have a molecularly confirmed *CRB1*-IRD in cases where they harbored two or more rare functional variants (i.e., disease-causing *CRB1* variants, such as missense, deletions, loss-of-function, or splice altering variants) affecting both gene copies of *CRB1* (Supplementary Table 1).

We excluded patients with systemic inflammatory conditions at the time of sampling and/or patients that received systemic immunomodulatory treatment. At the day of inclusion, patients were examined by visual acuity measurement, and slit lamp examination was performed by an experienced uveitis specialist for assessment of vitreous cells and vitreous haze.

Next, we obtained blood from 29 anonymous age-matched healthy blood bank donors (HC) with no history of ocular inflammatory disease who gave broad written informed consent at

the research blood bank of the University Medical Center Utrecht (The "Mini Donor Dienst").

Targeted blood proteomics

Venous blood samples were collected in EDTA Lavender Top Tubes (#362084, BD Biosciences, Franklin Lakes, USA) and then centrifuged for 10 min (400g) within an hour of blood collection (**Supplementary Table 2**). Plasma was transferred to a Falcon[™] 15 mL Conical Centrifuge Tube and centrifuged for 10 min (1500g), after which the cleared plasma was transferred and stored in Micronic 1.4 mL round bottom tubes (#MP32022, Micronic, Lelystad, the Netherlands) at -80 degrees Celsius. For proteomic analysis of plasma, patient and control samples were randomized over three 96 well plates (#72.1980, Sarstedt, Nümbrecht, Germany) and sealed (#232698, Thermo Fisher, Waltham, USA) prior to shipment to the Olink Proteomic facility at the Erasmus Medical Center, Rotterdam, the Netherlands. We used the *Olink Explore 384 Inflammation II* panel for targeted proteomics of blood plasma. This Olink technology is based on Proximity Extension Assays (PEA) coupled with NGS and is capable of the simultaneous relative quantification of 370 protein analytes.⁷

TaqMan® SNP genotyping

Genomic DNA of 59 peripheral mononuclear blood samples in RLT Plus lysis buffer (#1053393, Qiagen, Hilden, Germany) was isolated with the AllPrep DNA/RNA/miRNA Universal Kit (#80224, Qiagen, Hilden, Germany). Next, we determined the rs7535263

72 variant with the TaqMan® SNP genotyping technology (#4351379, Thermo Fisher, Waltham, 73 USA). Genotypes were called using QuantStudio 12K Flex software (Thermo Fisher, Waltham, USA). Linkage disequilibrium (r² or D') data for rs7535263 in the CEU population 74 of the 1000 genomes were obtained with the LDproxy tool with genome build GRCh37 in 75 76 LDlink. 19 The estimated recombination rate for CEU (build GRCh37) generated by Adam 77 Auton obtained via the 1000 Genomes was ftp site 78 (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507 omni recombination r 79 ates/).²⁰ We calculated the LD between rs7535263 in CFH and CRB1 missense variants 80 p.(Cys948Tyr) and p.(Arg764Cys) in phased whole-genome sequencing data of ~150,000 individuals of the UK Biobank using the --Id function in plink 2.0.21,22 The UK Biobank has 81 82 ethical approval from North West-Haydock Research Ethics Committee (REC reference: 83 16/NW/0274). Details of the UK Biobank study have been described in detail previously.²³ 84 This research has been conducted using the UK Biobank Resource under Application 85 Number 24711. 86 TagMan® genotyping of rs7535263 was also performed in an independent validation cohort 87 (Cohort II) of 123 CRB1-IRD patients from United Kingdom, Australia, Palestine, Italy, 88 France, Belgium, the Netherlands, Canada, Poland, Switzerland, South Africa, Lithuania, 89 Germany, and Ireland (MEC-2010-359) and 1292 Dutch controls from the amyotrophic lateral sclerosis study.²⁴ All patients provided written informed consent for genetic testing at 90 91 the centre of recruitment. CRB1-associated genetic diagnoses were made by targeted gene 92 Sanger sequencing or established recently through RP/LCA smMIPs sequencing.²⁵ 93 TagMan® SNP genotyping (#4351379, Thermo Fisher, Waltham, USA) was performed on 94 genomic DNA following the same procedure as described above by the laboratory of the 95 Department of Human Genetics, Radboud University Medical Center, Nijmegen, the 96 Netherlands.

Statistical analyses

Proteome analyses were performed on Normalized Protein eXpression (NPX) units from the output of the Olink analysis in R and R studio (version 4.2.2) using the Olink® Analyze R package. 26,27 One protein, TNFSF9, had 13 missing data points and 10 proteins did not pass quality control (Olink assay report). These proteins were removed prior to group analyses. The prcomp function of R base was used to perform principal component analysis (PCA). Differential expression analysis was performed using a likelihood ratio test (LRT) with age and sex as covariates in the models and we used the qvalue package from Bioconductor to correct P values for multiple testing.²⁸ Over-representation analysis (or enrichment) was performed on proteins with nominal significant differential expression levels (P<0.05) with the ClusterProfiler R package and using the WikiPathways database as a reference.29 The results were plotted using the dotplot function of the enrichplot R package and the P-values from enrichment analysis were adjusted with the Benjamini-Hochberg (BH) procedure, using the p.adjust function in R base, and P-values (Padj) <0.05 were considered statistically significant.30 Disease association for rs7535263 was assessed with Plink using the Fisher's exact test and expressed as the odds ratio with a 95% confidence interval. We performed a likelihood ratio test (LRT) to assess the relation between the genotype and the protein expression levels and visualized the results using the *corrplot* R package.³¹ Other figures were generated with the ggplot2 package. 32 The explained variance (R2) by the genotype of rs7535263 of plasma proteins was calculated using the squared Pearson correlation coefficient (r²) using the *cor* function in R base.

Results

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122


123

Generation of a high-quality plasma proteome of CRB1-IRD patients

To explore the composition of inflammatory mediators in the plasma proteome of *CRB1*-IRD patients, we conducted 370-plex targeted proteomics using proximity extension assays combined with *next-generation sequencing* in a cohort of 30 patients and 29 healthy controls. To ensure high-quality data for quantitative proteomic analysis, we first applied a

Complement factors in CRB1-IRDs

stringent quality control process. We first filtered out low-quality analytes by removing proximity extension assays that did not pass quality control in all plasma samples, resulting in 358 (97%) proteins that passed this filtering step. We detected no outlier plasma samples as shown by the relatively comparable sample median and sample interquartile range (IQR) as well as *Normalized Protein eXpression* (NPX, the protein expression unit which is in Log2 scale) distribution between plasma samples (**Figure 1A and 1B**). However, nine plasma samples exhibited internal controls deviating >0.3 NPX from the plate median which were also removed from the dataset (**Figure 1B**). Principal component analysis on the 50 remaining plasma samples revealed a moderate plate effect that we mitigated by using the *Combat* algorithm to account for batch effects (**Figure 1C and 1D**). As a result, a high-quality proteomic dataset was generated for downstream analysis.



137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

Complement factors in *CRB1*-IRDs

Figure 1. Quality control of plasma proteomic profiling by proximity extension assays combined with next generation sequencing. A) The median and the interquartile range (IQR) of the distribution of Normalized Protein eXpression (NPX) values for each of 59 plasma samples (in blue) measured in this study and internal plate and array controls (in grey). The horizontal and vertical dashed lines indicate +/- 2.5 standard deviations of all sample medians (x-axis) and IQR's (y-axis). B) The sample-wise distributions of NPX values for the Inflammation II panel. Boxplots of NPX values for each plasma sample along the x-axis and NPX values along the y-axis. The center line represents the median. Plasma samples are colored by "QC_Warning" (Warning = >0.3NPX from the median value of all samples on the plate). C-D) The first two principal components of 50 plasma samples and 359 proteins before and after batch correction with Combat.

Elevated concentrations of plasma complement factors in CRB1-IRD patients

We then compared the plasma proteome of patients to controls using linear models that include age and sex (likelihood ratio test). At a false discovery rate of 5% (q<0.05), we detected 10 proteins with significantly different abundance between patients and controls (Figure 2A and Supplementary Table 3). Among these, elevated levels were observed for Complement Factor I [CFI], Complement factor H [CFH], protein S [PROS1], Serpin family D member 1 [SERPIND1], and A Disintegrin-like And Metalloproteinase with ThromboSpondin type 1 [ADAMTS1] in patients compared to healthy controls (Figure 2B). We also detected significantly decreased levels for serine protease 22 [PRSS22] and microfibrillar-associated protein 4 [MFAP4] in CRB1-IRD patients. The 62 proteins most associated with CRB1-IRD patients (nominal P<0.05) showed overall considerable positive correlation in expression levels, with close clustering of CFI, CFH, C3, and SERPIND1 (Figure 2C). These 62 proteins were strongly enriched for pathways involving platelet biology, the complement system and coagulation cascades (Figure 2D and Supplementary Table 4). In detail, the most enriched pathway was the "Complement cascade" (e.g., Reactome pathway R-HSA-166658, Padj = $P = 3.03 \times 10^{-15}$, Figure 2D). In total, 12/62 CRB1-IRD associated proteins were linked to this pathway including the significantly elevated proteins CFH, CFI, and PROS1. In addition, PROS1 and SERPIND1

were also linked to coagulation pathways (i.e., "Formation of Fibrin Clot (Clotting Cascade)",

 $Padj = P = 4.69 \times 10^{-7}$). Another enriched pathway included the "Extracellular matrix organization" (R-HSA-1474244, $Padj = P = 5.84 \times 10^{-3}$) based on the significantly altered plasma proteins ADAMTS1 and MFAP4 (**Supplementary Table 4**). Collectively, these results show that elevated levels of complement factors and inflammation-related proteins characterized the plasma proteome of patients with *CRB1*-IRDs.




Figure 2. Plasma complement and coagulation proteins are associated with *CRB1*-IRDs. A) Volcano plot showing the -Log10(*P*-values) versus the Log2(mean NPX difference between groups) in plasma protein concentrations. Red indicates proteins with a significant increase in protein concentration and blue indicates proteins with a significant decrease in protein concentration in patients compared to controls. The dotted line indicates *P*<0.05. B) Scatter plots of the levels of Complement Factor I [CFI], A Disintegrin-like And Metalloproteinase with ThromboSpondin type 1 [ADAMTS1], protein S [PROS1], and Serpin family D member 1

[SERPIND1] in plasma of patients (orange) and controls (blue). The median and the interquartile range (IQR) of the distribution of Normalized Protein eXpression (NPX) values for each plasma sample is shown. **C)** Correlation plot of the 62 proteins most associated with *CRB1*-IRDs (*P*<0.05 from differential expression analysis). Red indicates a positive correlation, white indicates no correlation, and blue indicates a negative correlation between plasma protein analytes. **D)** Dot plot showing the top 10 results from enrichment analysis using the plasma proteins associated with *CRB1*-IRDs as shown in C.

The CFH genotype is altered in Dutch CRB1-IRD patients

On chromosome 1, the *CRB1* gene is located adjacent to the *CFH-CFHR* locus, which is implicated in other retinal conditions by influencing plasma complement protein levels and other proteins detected in our study. Therefore, we hypothesized that linkage between *CRB1* and the *CFH-CFHR* locus could influence the plasma proteome of *CRB1*-IRD patients. To investigate this, we genotyped the common intronic SNP rs7535263 (LD $r^2 = 1.0$ with AMD risk variant rs1410996 in CEU population of the 1000 Genomes). The genotype of rs7535263 was shown to have the strongest correlation with the gene expression levels of complement factors H related 1 to 4 (CFHR1-4) in *The Genotype-Tissue Expression* (GTEx) project and is associated with multiple retinal diseases (e.g., AMD, multifocal choroiditis, and serious chorioretinopathy) as well as with other immune mediators on our array, such as CFP.³³⁻⁴⁰

The LD signatures of rs7535263 (r^2 and D' with linked SNPs) and genetic recombination rates support that *CRB1* variants and *CFH-CFHR* variants may reside in the same haplotype block (**Figure 3A and 3B**). As expected, the allele frequency of rs7535263 of Dutch controls (A allele of rs7535263 = 0.34) was similar to that of the comparable North-European populations of the 1000 genomes (0.36 in GBR [British in England and Scotland] population). In contrast, the A allele of *CFH*-rs7535263 was significantly higher in frequency in patients compared to controls (A allele of rs7535263, odds ratio (OR) [95%CI = 2.85 [1.35-6.02], $P = 6.19 \times 10^{-3}$) (**Figure 3C and 3D**). The most common *CRB1* variant in our cohort was the homozygous p.(Met1041Thr) missense variants (*CRB1* c.3122T>C;

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

Complement factors in CRB1-IRDs

p.(Met1041Thr)) found in 11/30 patients (37% of patients) which has been previously linked to a large consanguineous pedigree originating from a genetically isolated population in the Netherlands (Figure 3E and 3F). While this variant is rare in the general European population (allele frequency = 0.00001 for rs62635656 in gnomAD database), the variant is found relatively more common (>1%) in this specific geographical Dutch area (Supplementary Table 1).41 We suspected that this deviation in allele frequency may therefore be the result of biological relatedness among cases (i.e., founder effect). All patients in our cohort homozygous for p.(Met1041Thr) were also homozygous for the A allele of rs7535263, which results in an excess of homozygotes for the A allele of the CFH variant rs7535263 and provides circumstantial evidence that biological relatedness between cases may likely influence our analysis of plasma complement factors. In a validation cohort of 123 CRB1-IRD cases from multiple countries and 1292 Dutch control participants the A allele of rs7535263 was not significantly more frequent in patients compared to controls (A allele of rs7535263, odds ratio (OR) [95%CI = 1.24 [0.95-1.61], P = 0.12). However, as in the first cohort, a skewed allele frequency was observed for rs7535263 for the most common CRB1 variant p.(Cys948Tyr), also a common CRB1 variant in previous reports. 42 which suggests linkage between specific variants of CRB1 and CFH. Data from large population databases such as the UK Biobank (UKB) may allow more accurate LD calculation between missense variants in CRB1 and rs7535263 in the CFH gene. To this end, we used phased whole-genome sequencing data from the UK Biobank from ~150,000 individuals and calculated LD for CRB1 missense variants. Two CRB1 missense variants commonly found in CRB1-IRD cases with UKB allele frequencies that allow meaningful LD calculations (allele frequency > 0.0001) display strong LD with rs7535263 in CFH;⁴³ the p.(Cys948Tyr) variant is in LD with the G allele of rs7535263 (D'=0.97, UKB) and the p.(Arg764Cys) T allele is in full LD (D' =1.0 in UKB) with the A allele of rs7535263. Collectively these results confirm our initial observation that patients with CRB1 missense variants may co-inherit functional variants in the adjacent CFH locus, which should be considered in quantitative analysis of plasma complement factors in CRB1-IRD patients.




Figure 3. Skewed allelic distribution for a common *CFH* variant in patients with *CRB1*-IRDs. A-B) Linkage disequilibrium (r2 metric left, and D' metric right) for rs7535263 in CEU superpopulation of the 1000 Genomes Project. Genes in the *complement factor H (CFH)* extended locus and *CRB1* are highlighted. C) Allele frequency distribution for rs7535263 in cohort 1 in cases and controls. D) The odds ratio, 95% confidence interval and *P*-value from Fischer's exact test for the A allele of rs7535263 in case-control analysis of cohort 1. E) The frequency of each *CRB1* pathogenic variant in cohort 1. F) Heatmap of the frequency of patients with rs7535263 genotype and *CRB1* Met1041Thr variant dosage in cohort 1.

CRB1-IRD patients show elevated plasma CFHR2 after adjusting for CFH genotype

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

We investigated the effect of rs7535263 on the plasma concentrations of immune mediators in healthy controls. In line with previous studies, the genotype of rs7535263 explained a significant proportion of the plasma levels of several proteins encoded by genes in the extended CFH-CFHR locus, including Complement factor H related protein 2 (CFHR2) (R2 = 0.36), and CFHR4 (R2 = 0.24), but not CFH (R2 = 0.003) (Supplementary Table 5 with R2 values), indicating that the genotype of this SNP may interfere with our analysis of some proteins in CRB1 patients. We therefore repeated our proteomic analysis for cohort 1 while correcting for the genotype of rs7535263 (along with sex and age). This analysis revealed that the association with the 10 significantly altered plasma proteins (q<0.05) in our initial group comparison were not significantly influenced by the genotype, such as CFI (q_{rs7535263} = 0.003), and CFH ($q_{rs7535263} = 0.06$) (Figure 4A and 4B, Supplementary Table 3) and all 10 remained within an FDR of 7% (q<0.07). However, adjusting for rs7535263 revealed additional proteins associated with CRB1-IRDs, most likely by improving statistical power by reducing residual variance. Among these plasma proteins was CFHR2 ($q_{187535263} = 0.04$), further supporting dysregulation of complement pathways in CRB1-IRDs (Figure 4A and **4B**). Correcting for rs7535263 also revealed significant association (q_{rs7535263}<0.05) with the DNA binding protein ZBP1, and RNA helicase DDX39A, which was previously also associated with the genotype of rs7535263 in multifocal choroiditis patients.³⁸ The identified complement factors CFI, CFH, and CFHR2 all target C3,44,45 an important downstream effector of the complement system which was also increased in CRB1-IRD patients, albeit at nominal significance (q = 0.064) (Figure 4D). Based on the profile of complement factors in our array (n = 18), we performed a correlation analysis to identify the factors associated with plasma C3 levels in our cohort. This analysis revealed that CFH and CFI, but not CFHR2, strongly correlated with the levels of plasma C3 (Figure 4C and 4D).




Figure 4. Elevated CFI and CFH levels correlate with plasma C3 in *CRB1*-IRDs. A) Results from differential expression analysis before (x-axis) and after (y-axis) corrected for the genotype of rs7535263. The -Log10(*P*-value) for each protein analyte is shown. Red indicates proteins that became statistically significantly different between cases and controls after adjusting for the genotype of rs7535263 and the color black indicates the 10 significant plasma proteins (q<0.05) in our initial group comparison. Purple highlights plasma proteins involved in complement pathways. The dotted line indicates *P*<0.05. B) Boxplots showing the levels for complement factor H [CFH] and complement factor H related 2 [CFHR2] in cases and controls in bulk and stratified by the genotype of *CFH* variant rs7535263. C) Correlation plot of the 18 proteins involved in complement pathways. Red indicates a positive correlation, white indicates no correlation, and blue indicates a negative correlation between plasma protein analytes. D) Boxplot and correlation plots of the levels of Complement Factor I [CFI], CFH, CFHR2, and complement component 3 [C3] in plasma in patients (orange) and controls (blue).

Discussion

In this study, we examined the plasma proteome of patients with *CRB1*-IRDs, whose levels of inflammation-related proteins and complement factors were notably elevated compared to healthy controls. A remarkable observation was the detection of elevated CFH and CFHR2

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

Complement factors in *CRB1*-IRDs

proteins in CRB1-IRDs because elevated plasma levels of CFHR2 have been linked with other eye conditions, including AMD and multifocal choroiditis patients. 12,33,34,38,46 CFH/CFHR proteins are all involved in the regulation of the complement component C3,45,47 which was supported by our observation of strong correlation between CFI and CFH with C3 in plasma. Our results are also in line with animal models of IRDs (rd10 mice), which show an increase in C3 protein levels and C3 activation, as well as an increase of mRNA of cfh, and cfi in the retina. 48 While C3 is important for complement activation and can cause microglial activation and photoreceptor cell injury. 49 it has also been shown to mediate retina-protective signaling in other murine models of retinal degeneration but will require human trials with (intravitreal) anti-C3 therapy to elucidate its potential as a therapeutic target for CRB1-IRDs. 48,50,51 Regardless, the increased levels of complement factors and inflammation-related proteins that we found in patients support immune-mediated pathways involved in CRB1-IRDs. Among the plasma proteins that were decreased in plasma of CRB1-IRD patients was the extracellular protein MFAP4 that is ubiquitously expressed and plays a role in intracellular interactions and cell adhesion. Macrophages drive local immune responses in retinal degeneration^{52,53} and MFAP4 loss affects macrophage differentiation in animal models.⁵⁴ The elevated plasma levels of ADAMTS1 detected in CRB1-IRD patients may be related to angiogenic responses, due to the vascular impairment secondary to degenerative changes in the retina. 55-58 The ADAMTS1 enzyme is an angiogenic matrix-modifying enzyme that is upregulated by pro-inflammatory conditions in the retinal pigment epithelium (RPE).⁵⁹ We also detected elevated levels of PROS1, a protein involved in the homeostasis of RPE. Whole-exome sequencing has previously identified homozygous pathogenic variants in the PROS1 gene as causing retinal dystrophy in two unrelated families, 60 potentially disrupting the vitamin K-dependent activities of PROS1, leading to RPE degradation. Further investigation is needed to determine whether the elevated levels of PROS1 are caused by retinal damage or by other biological events involving PROS1.

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

Complement factors in *CRB1*-IRDs

While the plasma proteome may reflect inflammation at the retinal level, it may also be influenced by functional variants in complement factor coding genes. The CRB1 gene is located on chromosome 1 immediately downstream of the CFH locus. SNPs in the CFH locus have been associated with several retinal conditions in which CFH/CFHR proteins were also altered, including AMD, central serous chorioretinopathy, and multifocal choroiditis, 33-39 indicating that this locus could be an important disease-modifying locus for eye conditions. Using TaqMan® SNP genotyping technology, we found evidence for skewed distribution of functional variants in the CFH gene which may predispose to altered complement factor levels in CRB1-IRDs or obscure relevant disease associations with plasma proteins, as demonstrated by our work. The significant skewing of the common CFH variants across CRB1 pathogenic variants in our Dutch cohort is likely the result of frequent consanguineous marriages in geographically more isolated populations, such as the strict geographical location of the p.(Met1041Thr) in the Netherlands and predisposes to homozygosity of harmful recessive alleles. Genotype frequencies, Hardy-Weinberg equilibrium assumptions, and allele frequencies can be affected by relatedness and our study demonstrates that addressing relatedness is crucial to ensure the accuracy of genotype-disease relationships and assessment of quantification of the complement factors in CRB1-IRDs and other familybased monogenic conditions. We believe this genetic "confounding" of common variants is currently strongly underappreciated in molecular profiling studies of CRB1-IRDs. While we show that in a second global cohort there is no association with the CFH/CFHR locus in CRB1 cases in general, data from the well-powered UK Biobank demonstrated linkage between variants in CFH and CRB1. Several key missense variants (e.g., p.(Cys948Tyr)) are nearly exclusively inherited with one of the two alleles of rs7535263, which tag functionally distinct CFH/CFHR haplotypes and predispose to altered composition of plasma complement factors. 11,12 This linkage is expected from their proximity on the genome and LD signatures in the general population and has important implications for

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

Complement factors in CRB1-IRDs

future research and treatment modalities: 1) Our study demonstrates that complement factor components are involved in CRB1-IRDs, but that relative biological relatedness (i.e., founder effects) between individuals or linkage with functional variants in the CFH locus should be considered in follow-up studies of complement dysregulation in human studies of CRB1-IRDs. 2) While we demonstrate that correcting for the genotype of rs7535263 revealed an otherwise obscured increase in CFHR2 levels in patients, it is not unlikely that additional CFH(R) gene variants that genetically predispose to altered complement factor levels contribute to the pathophysiology of CRB1-IRDs. The limited sample size of our study and the lack of probing for other CFH-related factors encoded by genes upstream of the CRB1 locus (e.g., CFHR1 and CFHR3 levels correlate with genotype of rs7535263 according to gtexportal) may have resulted in an underestimation of the differences in the levels of complement factors in CRB1-IRD patients compared to controls. 3) Many more common variants in immune genes are likely involved in disease-modifying pathways that may influence the severity and disease course of CRB1-IRDs. The use of genome-wide association studies using well defined clinical endpoints, preferably based on microperimetry,61 may aid in the discovery of these common variants and could improve genotype-phenotype correlations to better predict disease course, and perhaps lead to therapeutic modalities that can alter the disease course. The latter may be also of interest for emerging CRB1 gene-augmentation therapy or mutational correction by allelic substitution via CRISPR/Cas9-mediated homology-directed repair or base editing, 62,63 because these therapeutic approaches are accompanied by immune activation when administered intravitreally or subretinally.⁶⁴ It would be important to determine to what extent the inflammatory markers identified in this study may help understand the side effects of gene therapy, such as increased chorioretinal atrophy that has recently been described after gene therapy using voretigene neparvovec for RPE65-associated retinal dystrophies. 65,66 A major source of plasma complement components is the liver, but complement proteins are also produced and expressed in the retina, as well as by immune cells and various tissues. Complement activation may occur in the retina due to loss of tissue integrity caused by

CRB1 dysfunction, and modulating the complement system without addressing this primary cause may not have a clinically significant impact on the progression of the disease. Regardless, a complement-targeted therapy may be useful as a combination therapy to minimize adverse reactions from CRB1 gene correcting strategies in retinal degeneration, and potentially even in other gene therapy strategies for IRDs. In future studies, it might be informative to determine the immune profile of patients prior to commencing gene therapy interventions, to determine to what extent complement activation and plasma concentrations influence outcome in patients.

In conclusion, our results implicate the involvement of the complement cascade in CRB1-IRDs. For future research, gene association studies of all SNPs in the genome with a categorization of patients based on disease severity may provide more insight into the pathophysiology of CRB1-IRDs, and IRDs in general.

Acknowledgements

Dr. N.H. ten Dam-van Loon, Dr. J. Ossewaarde-van Norel, and Dr. V. Koopman-Kalinina Ayuso for their assistance performing slit lamp examination and assessment of vitreous cells and vitreous haze on all included patients.

References

- 378 1. Bujakowska K, Audo I, Mohand-Säid S, et al. CRB1 mutations in inherited retinal
- 379 dystrophies. Hum Mutat 2012;33:306. Available at: /pmc/articles/PMC3293109/ [Accessed
- 380 August 7, 2022].

- 381 2. Den Hollander Al, Heckenlively JR, van den Born Ll, et al. Leber congenital amaurosis
- 382 and retinitis pigmentosa with Coats-like exudative vasculopathy are associated with
- mutations in the crumbs homologue 1 (CRB1) gene. Am J Hum Genet 2001;69:198–203.
- 384 Available at: https://pubmed.ncbi.nlm.nih.gov/11389483/ [Accessed September 6, 2023].
- 385 3. Den Hollander Al, Davis J, Van Der Velde-Visser SD, et al. CRB1 mutation spectrum in
- inherited retinal dystrophies. Hum Mutat 2004;24:355–369. Available at:
- 387 https://pubmed.ncbi.nlm.nih.gov/15459956/ [Accessed September 6, 2023].
- 4. Talib M, Van Cauwenbergh C, De Zaeytijd J, et al. CRB1-associated retinal dystrophies in
- 389 a Belgian cohort: genetic characteristics and long-term clinical follow-up. British Journal of
- 390 Ophthalmology 2022;106:696–704. Available at: https://bjo-bmj-
- 391 com.proxy.library.uu.nl/content/106/5/696 [Accessed October 3, 2023].
- 392 5. Hettinga YM, van Genderen MM, Wieringa W, et al. Retinal Dystrophy in 6 Young Patients
- 393 Who Presented with Intermediate Uveitis. Ophthalmology 2016;123:2043–2046. Available
- 394 at: https://pubmed.ncbi.nlm.nih.gov/27157150/ [Accessed February 21, 2023].
- 395 6. Verhagen F, Kuiper J, Nierkens S, et al. Systemic inflammatory immune signatures in a
- 396 patient with CRB1 linked retinal dystrophy. Expert Rev Clin Immunol 2016;12:1359–1362.
- 397 Available at: https://pubmed.ncbi.nlm.nih.gov/27690673/ [Accessed February 21, 2023].
- 398 7. Watson CM, El-Asrag M, Parry DA, et al. Mutation screening of retinal dystrophy patients
- 399 by targeted capture from tagged pooled DNAs and next generation sequencing. PLoS One
- 400 2014;9. Available at: https://pubmed.ncbi.nlm.nih.gov/25133751/ [Accessed August 8, 2022].
- 401 8. De Castro-Miró M, Pomares E, Lorés-Motta L, et al. Combined genetic and high-
- 402 throughput strategies for molecular diagnosis of inherited retinal dystrophies. PLoS One
- 403 2014;9. Available at: https://pubmed.ncbi.nlm.nih.gov/24516651/ [Accessed August 8, 2022].
- 404 9. Alves CH, Wijnholds J. Microglial Cell Dysfunction in CRB1-Associated Retinopathies.
- 405 Adv Exp Med Biol 2019;1185:159–163. Available at: https://link-springer-
- 406 com.proxy.library.uu.nl/chapter/10.1007/978-3-030-27378-1_26 [Accessed August 8, 2022].
- 407 10. Moekotte L, Kuiper JJW, Hiddingh S, et al. CRB1-Associated Retinal Dystrophy Patients
- 408 Have Expanded Lewis Glycoantigen-Positive T Cells. Invest Ophthalmol Vis Sci 2023;64:6.
- 409 Available at: https://pubmed.ncbi.nlm.nih.gov/37792335/ [Accessed October 10, 2023].
- 410 11. Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome.
- 411 Nature 2018;558:73–79. Available at: https://pubmed.ncbi.nlm.nih.gov/29875488/ [Accessed
- 412 September 7, 2023].
- 413 12. Emilsson V, Gudmundsson EF, Jonmundsson T, et al. A proteogenomic signature of
- 414 age-related macular degeneration in blood. Nat Commun 2022;13. Available at:
- 415 https://pubmed.ncbi.nlm.nih.gov/35697682/ [Accessed September 7, 2023].
- 416 13. Lynch AM, Wagner BD, Mandava N, et al. The Relationship of Novel Plasma Proteins in
- 417 the Early Neonatal Period With Retinopathy of Prematurity. Invest Ophthalmol Vis Sci
- 418 2016;57:5076–5082. Available at: https://pubmed.ncbi.nlm.nih.gov/27679852/ [Accessed
- 419 September 7, 2023].
- 420 14. Kuiper JJW, Verhagen FH, Hiddingh S, et al. A Network of Serum Proteins Predict the
- 421 Need for Systemic Immunomodulatory Therapy at Diagnosis in Noninfectious Uveitis.
- 422 Ophthalmology science 2022;2. Available at: https://pubmed.ncbi.nlm.nih.gov/36245752/
- 423 [Accessed September 7, 2023].

- 424 15. Achten R, van Luijk C, Thijs J, et al. Non-Infectious Uveitis Secondary to Dupilumab
- 425 Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile. Ocul
- 426 Immunol Inflamm 2023. Available at: https://pubmed.ncbi.nlm.nih.gov/36854134/ [Accessed
- 427 September 7, 2023].
- 428 16. Wennink RAW, Ayuso VK, Tao W, et al. A Blood Protein Signature Stratifies Clinical
- 429 Response to csDMARD Therapy in Pediatric Uveitis. Transl Vis Sci Technol 2022;11.
- 430 Available at: https://pubmed.ncbi.nlm.nih.gov/35103800/ [Accessed September 7, 2023].
- 431 17. Wierenga APA, Cao J, Mouthaan H, et al. Aqueous Humor Biomarkers Identify Three
- 432 Prognostic Groups in Uveal Melanoma. Invest Ophthalmol Vis Sci 2019;60:4740–4747.
- 433 Available at: https://pubmed.ncbi.nlm.nih.gov/31731294/ [Accessed September 7, 2023].
- 434 18. Haq Z, Yang D, Psaras C, Stewart JM. Sex-Based Analysis of Potential Inflammation-
- Related Protein Biomarkers in the Aqueous Humor of Patients With Diabetes Mellitus. Transl
- 436 Vis Sci Technol 2021;10:1–8. Available at: https://pubmed.ncbi.nlm.nih.gov/34003946/
- 437 [Accessed September 7, 2023].
- 438 19. Machiela MJ, Chanock SJ. LDassoc: an online tool for interactively exploring genome-
- 439 wide association study results and prioritizing variants for functional investigation.
- 440 Bioinformatics 2018;34:887–889. Available at: https://pubmed.ncbi.nlm.nih.gov/28968746/
- 441 [Accessed September 7, 2023].
- 442 20. Anon. Index of /vol1/ftp/technical/working/20130507_omni_recombination_rates.
- 443 Available at:
- https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination
- 445 _rates/ [Accessed October 10, 2023].
- 446 21. Chang CC, Chow CC, Tellier LCAM, et al. Second-generation PLINK: rising to the
- 447 challenge of larger and richer datasets. Gigascience 2015;4. Available at:
- 448 https://pubmed.ncbi.nlm.nih.gov/25722852/ [Accessed October 4, 2023].
- 22. Hofmeister RJ, Ribeiro DM, Rubinacci S, Delaneau O. Accurate rare variant phasing of
- 450 whole-genome and whole-exome sequencing data in the UK Biobank. Nat Genet
- 451 2023;55:1243–1249. Available at: https://pubmed.ncbi.nlm.nih.gov/37386248/ [Accessed
- 452 October 10, 2023].
- 453 23. Yeung MW, Wang S, Van De Vegte YJ, et al. Twenty-Five Novel Loci for Carotid Intima-
- 454 Media Thickness: A Genome-Wide Association Study in >45 000 Individuals and Meta-
- 455 Analysis of >100 □ 000 Individuals. Arterioscler Thromb Vasc Biol 2022;42:484–501.
- 456 Available at: https://www-ahajournals-
- 457 org.proxy.library.uu.nl/doi/abs/10.1161/ATVBAHA.121.317007 [Accessed October 10, 2023].
- 458 24. van Rheenen W, van der Spek RAA, Bakker MK, et al. Common and rare variant
- 459 association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic
- architectures and neuron-specific biology. Nat Genet 2021;53:1636–1648. Available at:
- 461 https://pubmed.ncbi.nlm.nih.gov/34873335/ [Accessed November 2, 2023].
- 462 25. Panneman DM, Hitti-Malin RJ, Holtes LK, et al. Cost-effective sequence analysis of 113
- 463 genes in 1,192 probands with retinitis pigmentosa and Leber congenital amaurosis. Front
- 464 Cell Dev Biol 2023;11. Available at: https://pubmed.ncbi.nlm.nih.gov/36819107/ [Accessed
- 465 September 26, 2023].
- 466 26. Anon. Olink Data normalization and standardization.
- 467 27. Anon. Facilitate Analysis of Proteomic Data from Olink [R package OlinkAnalyze version
- 468 3.5.1]. 2023. Available at: https://CRAN.R-project.org/package=OlinkAnalyze [Accessed
- 469 October 11, 2023].
- 470 28. Storey J, Bass A, Dabney A, Robinson D. qvalue: Q-value estimation for false discovery
- 471 rate control. 2023.

- 472 29. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting
- 473 omics data. Innovation (Cambridge (Mass)) 2021;2. Available at:
- 474 https://pubmed.ncbi.nlm.nih.gov/34557778/ [Accessed April 4, 2023].
- 475 30. Anon. Chapter 15 Visualization of functional enrichment result | Biomedical Knowledge
- 476 Mining using GOSemSim and clusterProfiler. Available at: https://yulab-smu.top/biomedical-
- 477 knowledge-mining-book/enrichplot.html [Accessed April 4, 2023].
- 478 31. Wei T, Simko V. R package "corrplot": Visualization of a Correlation Matrix. 2021.
- 479 32. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2016.
- 480 33. Cipriani V, Lorés-Motta L, He F, et al. Increased circulating levels of Factor H-Related
- Protein 4 are strongly associated with age-related macular degeneration. Nat Commun
- 482 2020;11. Available at: https://pubmed.ncbi.nlm.nih.gov/32034129/ [Accessed September 7,
- 483 2023]
- 484 34. Lorés-Motta L, van Beek AE, Willems E, et al. Common haplotypes at the CFH locus and
- 485 low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations
- and age-related macular degeneration. Am J Hum Genet 2021;108:1367–1384. Available at:
- 487 https://pubmed.ncbi.nlm.nih.gov/34260947/ [Accessed September 7, 2023].
- 488 35. den Hollander Al, Mullins RF, Orozco LD, et al. Systems genomics in age-related
- 489 macular degeneration. Exp Eye Res 2022;225. Available at:
- 490 https://pubmed.ncbi.nlm.nih.gov/36108770/ [Accessed September 7, 2023].
- 491 36. Kaye R, Chandra S, Sheth J, et al. Central serous chorioretinopathy: An update on risk
- factors, pathophysiology and imaging modalities. Prog Retin Eye Res 2020;79. Available at:
- 493 https://pubmed.ncbi.nlm.nih.gov/32407978/ [Accessed September 7, 2023].
- 494 37. Schellevis RL, Van Dijk EHC, Breukink MB, et al. Role of the Complement System in
- 495 Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study. JAMA
- 496 Ophthalmol 2018;136:1128–1136. Available at: https://pubmed.ncbi.nlm.nih.gov/30073298/
- 497 [Accessed September 7, 2023].
- 498 38. de Groot EL, Ossewaarde-van Norel J, de Boer JH, et al. Association of Risk Variants in
- 499 the CFH Gene With Elevated Levels of Coagulation and Complement Factors in Idiopathic
- 500 Multifocal Choroiditis. JAMA Ophthalmol 2023;141. Available at:
- 501 https://pubmed.ncbi.nlm.nih.gov/37410486/ [Accessed September 7, 2023].
- 39. Ferrara DC, Merriam JE, Freund KB, et al. Analysis of major alleles associated with age-
- 503 related macular degeneration in patients with multifocal choroiditis: strong association with
- 504 complement factor H. Arch Ophthalmol 2008;126:1562–1566. Available at:
- 505 https://pubmed.ncbi.nlm.nih.gov/19001225/ [Accessed September 7, 2023].
- 506 40. Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma
- 507 proteome with genetics and disease. Nat Genet 2021;53:1712–1721. Available at:
- https://pubmed.ncbi.nlm.nih.gov/34857953/ [Accessed September 7, 2023].
- 41. Den Hollander Al, Ten Brink JB, De Kok YJM, et al. Mutations in a human homologue of
- 510 Drosophila crumbs cause retinitis pigmentosa (RP12). Nat Genet 1999;23:217–221.
- 511 Available at: https://pubmed.ncbi.nlm.nih.gov/10508521/ [Accessed September 7, 2023].
- 42. Kousal B, Dudakova L, Gaillyova R, et al. Phenotypic features of CRB1-associated early-
- 513 onset severe retinal dystrophy and the different molecular approaches to identifying the
- 514 disease-causing variants. Graefes Arch Clin Exp Ophthalmol 2016;254:1833–1839.
- 515 Available at: https://pubmed.ncbi.nlm.nih.gov/27113771/ [Accessed September 7, 2023].
- 43. Lopes da Costa B, Kolesnikova M, Levi SR, et al. Clinical and Therapeutic Evaluation of
- 517 the Ten Most Prevalent CRB1 Mutations. Biomedicines 2023;11. Available at:
- 518 https://pubmed.ncbi.nlm.nih.gov/36830922/ [Accessed October 4, 2023].

- 519 44. Whaley K, Ruddy S. Modulation of C3b hemolytic activity by a plasma protein distinct
- 520 from C3b inactivator. Science 1976;193:1011–1013. Available at:
- 521 https://pubmed.ncbi.nlm.nih.gov/948757/ [Accessed September 7, 2023].
- 45. Eberhardt HU, Buhlmann D, Hortschansky P, et al. Human factor H-related protein 2
- 523 (CFHR2) regulates complement activation. PLoS One 2013;8. Available at:
- https://pubmed.ncbi.nlm.nih.gov/24260121/ [Accessed September 7, 2023].
- 525 46. Cipriani V, Tierney A, Griffiths JR, et al. Beyond factor H: The impact of genetic-risk
- 526 variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-
- 527 related protein concentrations. Am J Hum Genet 2021;108:1385–1400. Available at:
- 528 https://pubmed.ncbi.nlm.nih.gov/34260948/ [Accessed September 7, 2023].
- 529 47. Cserhalmi M, Papp A, Brandus B, et al. Regulation of regulators: Role of the
- complement factor H-related proteins. Semin Immunol 2019;45. Available at:
- https://pubmed.ncbi.nlm.nih.gov/31757608/ [Accessed September 7, 2023].
- 532 48. Silverman SM, Ma W, Wang X, et al. C3- and CR3-dependent microglial clearance
- protects photoreceptors in retinitis pigmentosa. J Exp Med 2019;216:1925–1943.
- 49. Wang S, Du L, Yuan S, Peng GH. Complement C3a receptor inactivation attenuates
- retinal degeneration induced by oxidative damage. Front Neurosci 2022;16. Available at:
- 536 https://pubmed.ncbi.nlm.nih.gov/36110094/ [Accessed September 7, 2023].
- 50. Hoh Kam J, Lenassi E, Malik TH, et al. Complement component C3 plays a critical role
- 538 in protecting the aging retina in a murine model of age-related macular degeneration. Am J
- 539 Pathol 2013;183:480–492. Available at: https://pubmed.ncbi.nlm.nih.gov/23747511/
- 540 [Accessed September 7, 2023].
- 51. Wykoff CC, Hershberger V, Eichenbaum D, et al. Inhibition of Complement Factor 3 in
- 542 Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J
- 543 Ophthalmol 2022;235:131–142. Available at: https://pubmed.ncbi.nlm.nih.gov/34509438/
- 544 [Accessed September 7, 2023].
- 545 52. Yu C, Roubeix C, Sennlaub F, Saban DR. Microglia versus Monocytes: Distinct Roles in
- 546 Degenerative Diseases of the Retina. Trends Neurosci 2020;43:433–449. Available at:
- 547 https://pubmed.ncbi.nlm.nih.gov/32459994/ [Accessed September 7, 2023].
- 548 53. Guo M, Schwartz TD, Dunaief JL, Cui QN. Myeloid cells in retinal and brain
- 549 degeneration. FEBS J 2022;289:2337–2361. Available at:
- 550 https://pubmed.ncbi.nlm.nih.gov/34478598/ [Accessed September 7, 2023].
- 551 54. Ong SLM, de Vos IJHM, Meroshini M, et al. Microfibril-associated glycoprotein 4 (Mfap4)
- regulates haematopoiesis in zebrafish. Sci Rep 2020;10. Available at:
- 553 https://pubmed.ncbi.nlm.nih.gov/32678226/ [Accessed September 7, 2023].
- 55. Rajabian F, Arrigo A, Bianco L, et al. Optical Coherence Tomography Angiography in
- 555 CRB1-Associated Retinal Dystrophies. J Clin Med 2023;12. Available at:
- 556 https://pubmed.ncbi.nlm.nih.gov/36769743/ [Accessed September 7, 2023].
- 557 56. Murro V, Mucciolo DP, Sodi A, et al. Retinal capillaritis in a CRB1-associated retinal
- 558 dystrophy. Ophthalmic Genet 2017;38:555–558. Available at:
- 559 https://doi.org/10.1080/13816810.2017.1281966.
- 560 57. Alonso F, Dong Y, Li L, et al. Fibrillin-1 regulates endothelial sprouting during
- angiogenesis. Proc Natl Acad Sci U S A 2023;120. Available at:
- https://pubmed.ncbi.nlm.nih.gov/37252964/ [Accessed September 7, 2023].
- 563 58. Talib M, van Schooneveld MJ, van Genderen MM, et al. Genotypic and Phenotypic
- 564 Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study.
- Ophthalmology 2017;124:884–895. Available at: https://pubmed.ncbi.nlm.nih.gov/28341475/
- 566 [Accessed February 21, 2023].

- 567 59. Bevitt DJ, Mohamed J, Catterall JB, et al. Expression of ADAMTS metalloproteinases in
- the retinal pigment epithelium derived cell line ARPE-19: Transcriptional regulation by TNFα.
- 569 Biochimica et Biophysica Acta Gene Structure and Expression 2003;1626:83–91. Available
- at: https://pubmed.ncbi.nlm.nih.gov/12697333/ [Accessed September 7, 2023].
- 571 60. Bushehri A, Zare-Abdollahi D, Alavi A, et al. Identification of PROS1 as a Novel
- 572 Candidate Gene for Juvenile Retinitis Pigmentosa. Int J Mol Cell Med 2019;8:179–190.
- 573 Available at: https://pubmed.ncbi.nlm.nih.gov/32489947/ [Accessed September 7, 2023].
- 574 61. Nguyen XTA, Talib M, van Schooneveld MJ, et al. CRB1-Associated Retinal
- 575 Dystrophies: A Prospective Natural History Study in Anticipation of Future Clinical Trials. Am
- J Ophthalmol 2022;234:37–48. Available at: https://pubmed.ncbi.nlm.nih.gov/34320374/
- 577 [Accessed October 3, 2023].
- 578 62. Boon N, Lu X, Andriessen CA, et al. AAV-mediated gene augmentation therapy of CRB1
- 579 patient-derived retinal organoids restores the histological and transcriptional retinal
- 580 phenotype. Stem Cell Reports 2023;18:1123–1137. Available at:
- 581 https://pubmed.ncbi.nlm.nih.gov/37084726/ [Accessed September 7, 2023].
- 582 63. da Costa BL, Li Y, Levi SR, et al. Generation of CRB1 RP Patient-Derived iPSCs and a
- 583 CRISPR/Cas9-Mediated Homology-Directed Repair Strategy for the CRB1 c.2480G>T
- 584 Mutation. Adv Exp Med Biol 2023;1415:571–576. Available at:
- https://pubmed.ncbi.nlm.nih.gov/37440088/ [Accessed September 7, 2023].
- 586 64. Nguyen X-T-A, Moekotte L, Plomp AS, et al. Retinitis Pigmentosa: Current Clinical
- 587 Management and Emerging Therapies. Int J Mol Sci 2023;24:7481. Available at:
- 588 https://www.mdpi.com/1422-0067/24/8/7481 [Accessed April 19, 2023].
- 589 65. Gange WS, Sisk RA, Besirli CG, et al. Perifoveal Chorioretinal Atrophy after Subretinal
- 590 Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis. Ophthalmol
- 591 Retina 2022;6:58-64. Available at: https://pubmed.ncbi.nlm.nih.gov/33838313/ [Accessed
- 592 September 7, 2023].

- 593 66. Reichel FF, Seitz I, Wozar F, et al. Development of retinal atrophy after subretinal gene
- therapy with voretigene neparvovec. Br J Ophthalmol 2023:107. Available at:
- 595 https://pubmed.ncbi.nlm.nih.gov/35609955/ [Accessed September 7, 2023].

